Reframe Daily: Diet calms psoriasis; bug-repellent baby wraps cut malaria; twin CAR-T helps lupus

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A Mediterranean-style diet eased psoriasis in a randomized trial; permethrin-treated baby wraps lowered malaria in infants; giving two kinds of CAR-T cells sent hard-to-treat lupus into remission for many patients in a phase 1 trial; a PD-1/LAG-3 antibody combo boosted tumor response before melanoma surgery; and a next-gen RNA rabies shot kept strong protection for months in its first human study.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A Mediterranean-style eating plan helped calm psoriasis symptoms when added to usual topical care.

Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂🙂 (already “on the shelf”—food + dietitian support; can be used now alongside standard care). 

Good news: Simple baby wraps soaked with insect repellent cut malaria episodes in young kids, even where bed nets are used.

Permethrin-Treated Baby Wraps for the Prevention of Malaria

Market readiness: 🙂🙂🙂🙂 (ingredients and textiles exist today; scale-up and local rollout needed—especially outside the US market). 

Good news: Combining two kinds of CAR-T cells helped people with hard-to-treat lupus reach remission in a first-in-human study.

Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial

Market readiness: 🙂🙂 (early phase; hospital-based cell therapy—needs larger trials and FDA review). 

Good news: Before surgery, a new antibody combo that blocks PD-1 and LAG-3 boosted anti-tumor responses in melanoma in an early randomized trial.

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 MORPHEUS-Melanoma trial

Market readiness: 🙂🙂 (promising but still early; needs phase 3 confirmation and approvals). 

Good news: A next-gen self-amplifying RNA vaccine kept strong immune responses for months in its first human study.

Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open-label clinical trial

Market readiness: 🙂🙂 (platform in phase 1; multiple trials and regulatory steps ahead).

Thank you for taking the time to take care of yourself and your loved ones.